N. Bouck

发表

Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1.

K. Dameron, O. Volpert, M. Tainsky, 1994, Science.

N. Bouck, V. Stellmach, S. Hsu, 1996, Advances in cancer research.

Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration.

O. Volpert, N. Bouck, Olga Volpert, 2002, American journal of ophthalmology.

Induction of a step in carcinogenesis that is normally associated with mutagenesis by nonmutagenic concentrations of 5-azacytidine

N. Bouck, D. Kokkinakis, J. Ostrowsky, 1984 .

Coordinate control of anchorage independence, actin cytoskeleton, and angiogenesis by human chromosome 1 in hamster-human hybrids.

N. Bouck, P. Polverini, A. Stoler, 1986, Cancer research.

Inhibition of angiogenesis by thrombospondin-2.

O. Volpert, N. Bouck, D. Mosher, 1995, Biochemical and biophysical research communications.

Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin.

M. Stack, J. Enghild, H. Schnaper, 1996, Cancer research.

Phagocyte‐Mediated Carcinogenesis: DNA from Phagocyte‐Transformed C3H 10T1/2 Cells Can Transform NIH/3T3 Cells a

S. Weitzman, N. Bouck, C. Stevens, 1988, Annals of the New York Academy of Sciences.

Retinoic acid induces cells cultured from oral squamous cell carcinomas to become anti-angiogenic.

N. Bouck, M. Lingen, P. Polverini, 1996, The American journal of pathology.

Retinoic Acid and Interferon α Act Synergistically as Antiangiogenic and Antitumor Agents against Human Head and Neck Squamous Cell Carcinoma

N. Bouck, M. Lingen, P. Polverini, 1998 .

Somatic mutation as the basis for malignant transformation of BHK cells by chemical carcinogens

N. Bouck, Giampiero di Mayorca, G. Mayorca, 1976, Nature.

Identification of a single chromosome in the normal human genome essential for suppression of hamster cell transformation.

N. Bouck, A. Stoler, 1985, Proceedings of the National Academy of Sciences of the United States of America.

α1‐antitrypsin inhibits angiogenesis and tumor growth

O. Volpert, N. Bouck, T. Nelius, 2004 .

Alpha1-antitrypsin inhibits angiogenesis and tumor growth.

S. Campbell, O. Volpert, N. Bouck, 2004, International journal of cancer.

Molecular mediators of angiogenesis in bladder cancer.

S. Campbell, O. Volpert, N. Bouck, 1998, Cancer research.

PEDF: anti-angiogenic guardian of ocular function.

N. Bouck, 2002, Trends in molecular medicine.

Thrombospondin-1 Is a Major Activator of TGF-β1 In Vivo

R. Hynes, G. Boivin, N. Bouck, 1998, Cell.

Benzo[a]pyrene diol-epoxides: different mutagenic efficiency in human and bacterial cells.

N. Bouck, W. E. Fahl, C. Stevens, 1985, Mutation research.

The anticancer drug edelfosine is a potent inhibitor of neovascularization in vivo.

O. Volpert, N. Bouck, E. Ades, 1998, Cancer investigation.

Localization of the angiogenesis inhibitor thrombospondin in human synovial tissues.

G. Haines, N. Bouck, A. Koch, 1993, Pathobiology : journal of immunopathology, molecular and cellular biology.

Large-T-antigen-p53 complex formation is not cold sensitive in a cold-sensitive transformant induced by simian virus 40 mutant tsA1499

N. Bouck, J. Fikes, M. Rundell, 1984, Journal of virology.

The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin.

K. Dameron, O. Volpert, M. Tainsky, 1994, Cold Spring Harbor symposia on quantitative biology.

The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin.

M. Stack, J. Enghild, O. Volpert, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Tumor angiogenesis: the role of oncogenes and tumor suppressor genes.

N. Bouck, 1990, Cancer cells.

A novel simian virus 40 early-region domain mediates transactivation of the cyclin A promoter by small-t antigen and is required for transformation in small-t antigen-dependent assays

N. Bouck, K. Rundell, B. Henglein, 1996, Journal of virology.

New region of the simian virus 40 genome required for efficient viral transformation.

N. Bouck, T. Shenk, P. Berg, 1978, Proceedings of the National Academy of Sciences of the United States of America.

The distal region of the long arm of human chromosome 1 carries tumor suppressor activity for a human fibrosarcoma line.

N. Bouck, K. Klein, 1994, Cancer genetics and cytogenetics.

Separation of lytic and transforming functions of the simian virus 40 A region: two mutants which are temperature sensitive for lytic functions have opposite effects on transformation

N. Bouck, D. Pintel, G. di Mayorca, 1981, Journal of virology.

Characterization of a new simian virus 40 mutant, tsA3900, isolated from deletion mutant tsA1499

N. Bouck, T. Shenk, M. M. Pater, 1985, Journal of virology.

SV40 mutant tsA1499 is heat-sensitive for lytic growth but generates cold-sensitive rat-cell transformants.

N. Bouck, T. Shenk, D. Pintel, 1980, Cold Spring Harbor symposia on quantitative biology.

Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene

Peter J. Polverini, N. Bouck, F. Rastinejad, 1989, Cell.

Genetic assessment of the strength of a cancer suppressor gene in hamster cells.

K. Bauer, N. Bouck, S. Tolsma, 1988, Cancer research.

Chemical carcinogens transform BHK cells by inducing a recessive mutation

N. Bouck, G. di Mayorca, 1982, Molecular and cellular biology.

Induction of a step in carcinogenesis that is normally associated with mutagenesis by nonmutagenic concentrations of 5-azacytidine

N. Bouck, D. Kokkinakis, J. Ostrowsky, 1984, Molecular and cellular biology.

The relationship between DNA synthesis and conjugation in Escherichia coli.

N. Bouck, E. Adelberg, 1963, Biochemical and biophysical research communications.

Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.

W. Benedict, O. Volpert, N. Bouck, 1999, Science.

Keratinocyte growth factor induces angiogenesis and protects endothelial barrier function.

O. Volpert, N. Bouck, C. Waters, 1999, Journal of cell science.

Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium–derived factor

O. Volpert, N. Bouck, W. Zhou, 2002, Nature Medicine.

c-Jun N-terminal kinase activation is required for the inhibition of neovascularization by thrombospondin-1

M. Karin, O. Volpert, N. Bouck, 2001, Oncogene.

Maspin is an angiogenesis inhibitor

O. Volpert, N. Bouck, Ming Zhang, 2000, Nature Medicine.

Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1

O. Volpert, N. Bouck, S. Crawford, 2000, Nature Medicine.

CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells

David W. Dawson, Roy L. Silverstein, R. Hynes, 1997, The Journal of cell biology.

Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity

O. Volpert, N. Bouck, P. Polverini, 1993, The Journal of cell biology.

Pigment epithelium–derived factor regulates the vasculature and mass of the prostate and pancreas

N. Bouck, Chung Lee, S. Crawford, 2003, Nature Medicine.

Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat.

O. Volpert, N. Bouck, J. Henkin, 1999, Molecular pharmacology.

The dissociation of the surface architecture described by enhanced lectin agglutinability and the transformed phenotype expressed as anchorage independence

N. Bouck, K. D. Noonan, G. di Mayorca, 1977, Journal of cellular physiology.

Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis.

G. Haines, N. Bouck, A. Koch, 1998, Clinical immunology and immunopathology.

The majority of independently transformed BHK cell clones share a single functional lesion which determines anchorage independence and influences tumorigenicity

N. Bouck, M. Head, 1985, In Vitro Cellular & Developmental Biology.

Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma.

N. Bouck, M. Lingen, P. Polverini, 1998, Cancer research.

Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1.

T. Mikkelsen, O. Volpert, N. Bouck, 1996, Cancer research.

Multiple forms of angiostatin induce apoptosis in endothelial cells.

N. Bouck, S. Mandriota, G. Grau, 1998, Blood.

A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin.

M. L. Le Beau, N. Bouck, F. Rastinejad, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Inhibition of Angiogenesis by Interleukin 4

J. Peterson, O. Volpert, N. Bouck, 1998, The Journal of experimental medicine.

Stimulation and inhibition of angiogenesis by placental proliferin and proliferin-related protein.

D. Jackson, O. Volpert, N. Bouck, 1994, Science.

Thrombospondin‐1, vascular endothelial growth factor and fibroblast growth factor‐2 are key functional regulators of angiogenesis in the prostate

N. Bouck, S. Crawford, M. Pins, 2001, The Prostate.

Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis.

O. Volpert, N. Bouck, W. Schmiegel, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Tumour suppressor genes and angiogenesis: the role of TP53 in fibroblasts.

R. Hynes, O. Volpert, N. Bouck, 1996, European journal of cancer.

Angiogenesis: a mechanism by which oncogenes and tumor suppressor genes regulate tumorigenesis.

N. Bouck, 1992, Cancer treatment and research.

Peroxisome proliferator-activated receptor gamma ligands improve the antitumor efficacy of thrombospondin peptide ABT510.

Emelyn H. Shroff, S. Campbell, O. Volpert, 2004, Molecular cancer research : MCR.

Peroxisome Proliferator-Activated Receptor ; Ligands Improve the Antitumor Efficacy of Thrombospondin Peptide ABT 510

Emelyn H. Shroff, S. Campbell, O. Volpert, 2004 .

Thrombospondin as an Inhibitor of Angiogenesis

N. Bouck, D. Dawson, 1999 .

A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1.

O. Volpert, N. Bouck, J. Lawler, 1998, Proceedings of the National Academy of Sciences of the United States of America.

In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects.

O. Volpert, N. Bouck, P. Clézardin, 2001, Genes & development.

Interactions between hyperthermia and irradiation in two human lymphoblastic leukemia cell lines in vitro.

N. Bouck, R. Mulcahy, J. Cohen, 1988, Cancer research.

A Pilot Trial of Suramin in Metastatic Breast Cancer to Assess Antiangiogenic Activity in Individual Patients

A. Rademaker, W. Gradishar, N. Bouck, 2000, Oncology.

Thrombospondin-1 is a major activator of TGF-beta1 in vivo.

R. Hynes, G. Boivin, N. Bouck, 1998, Cell.

Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor

N. Bouck, S. Crawford, Wei Zhou, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Anti-cancer dividends from captopril and other inhibitors of angiogenesis.

N. Bouck, S. Campbell, 1998, Journal of nephrology.

The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression

O. Volpert, N. Bouck, V. Stellmach, 2004, Breast Cancer Research and Treatment.

Lumen formation and other angiogenic activities of cultured capillary endothelial cells are inhibited by thrombospondin-1.

M. Stack, N. Bouck, S. Tolsma, 1997, Microvascular research.

Thrombospondin-1 gene expression affects survival and tumor spectrum of p53-deficient mice.

R. Hynes, R. Bronson, N. Bouck, 2001, The American journal of pathology.

The role of hypoxia and p53 in the regulation of angiogenesis in bladder cancer.

N. Smith, S. Campbell, N. Bouck, 2001, The Journal of urology.

The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin

M. Stack, J. Enghild, O. Volpert, 1997 .

Loss of cancer suppressors, a driving force in carcinogenesis.

N. Bouck, B. Benton, 1989, Chemical research in toxicology.

The Effect of Captopril on Neovascularization Induced by bFGF in the Rat Cornea

Mark D. Johnson, O. Volpert, N. Bouck, 2013 .

Inhibition of tumor growth by systemic treatment with thrombospondin‐1 peptide mimetics

C. Dinney, O. Volpert, N. Bouck, 2002, International journal of cancer.

The insulin-like growth factor II/mannose 6-phosphate receptor is required for proliferin-induced angiogenesis.

D. Jackson, O. Volpert, N. Bouck, 1996, Endocrinology.

Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats.

O. Volpert, N. Bouck, D. Solt, 1996, The Journal of clinical investigation.

Assay and purification of naturally occurring inhibitor of angiogenesis.

N. Bouck, F. Rastinejad, P. Polverini, 1991, Methods in enzymology.

Inhibition of angiogenesis by tissue inhibitor of metalloproteinase

Mark D. Johnson, N. Bouck, H. Kim, 1994, Journal of cellular physiology.

Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity.

O. Volpert, N. Bouck, M. Ranalli, 2001, Journal of cell science.

Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity

K. Dameron, O. Volpert, N. Bouck, 1997, Oncogene.

P53 and angiogenesis.

N. Bouck, 1996, Biochimica et biophysica acta.

Original Paper Tumour Suppressor Genes and Angiogenesis: the Role of 7P53 in Fibroblasts

N. Bouck, J. Lawler, V. Stellmach, 1996 .

The angiogenic switch in hamster buccal pouch keratinocytes is dependent on TGFbeta-1 and is unaffected by ras activation.

N. Bouck, D. Solt, M. Lingen, 1997, Carcinogenesis.

Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells.

N. Bouck, M. Lingen, P. Polverini, 1996, Laboratory investigation; a journal of technical methods and pathology.

Mechanism of Action of Nalidixic Acid on Conjugating Bacteria

N. Bouck, E. Adelberg, 1970, Journal of bacteriology.

Partial inhibition of postreplication repair and enhanced frequency of chemical transformation in rat cells infected with leukemia virus.

N. Bouck, R. Waters, N. Mishra, 1977, Proceedings of the National Academy of Sciences of the United States of America.

Evaluation of chemical carcinogenicity by in vitro neoplastic transformation.

N. Bouck, G. di Mayorca, 1979, Methods in enzymology.

Diagnostic ultrasound is unable to enhance the rate of neoplastic transformation in cultured mammalian cells.

J. Chmiel, E. Madsen, N. Bouck, 1991, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy

G. Lang, B. Boehm, O. Volpert, 2003, Diabetologia.

Leukemia virus infection of mammalian cells: effect on two "transformation-associated" surface properties

N. Bouck, P. J. Wright, K. D. Noonan, 1976, Journal of virology.

Sister chromatid exchange analysis of human cells exposed to diagnostic levels of ultrasound.

E. Madsen, N. Bouck, R. Sabbagha, 1991, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.